Fig. 3
Cumulative NMA results for overall survival: reference case including RCTs with 100% HER2+ patients and HER2+ subgroups. a AC-TH52 weeks vs. AC-T, b TCH52 weeks vs. AC-T, c AC-TH52 weeks vs. TCH52 weeks, and d corresponding sample sizes and number of events. Boxes on the forest plots represent the hazard ratios, with 95% CrIs shown by the horizontal lines. The size of each box is based on the precision of each effect estimate, calculated as the inverse of the variance (precision = 1/SE2, where SE is a standard error). The x axis is presented in log-format. Probability better values are based on the random effects model. The dashed circle represents the maximum p(better) value that is possible: 100%. AC anthracycline (doxorubicin, epirubicin) + cyclophosphamide, CrI credible interval, H Herceptin® intravenous (IV), NA not available, OS overall survival, P(better) probability better, T taxane (docetaxel, paclitaxel), TCH docetaxel + carboplatin + Herceptin® IV